About Us

Developing cutting- edge cell therapies.

BioSyngen was established in Singapore on 1 July 2016 as an immuno-oncology company. It collaborates with leading biomedical research and clinical institutes in Germany, Australia, China and Singapore


Giving Cancer
Patients a
Second Chance


Developing cutting-edge immunotherapies to address unmet needs in oncology.

Advancing R&D through our network of international partners.

Achieving better outcomes for cancer patients

Core Management

Director & CMO

Dr. Han Deping

Chief Scientist

Prof. Jean Paul Thiery

Director & COO

Dr. Michelle Chen


Isaac Chow

Director & cso

Dr. Cecilia zhang


Vincent Zheng

Our facilities


Company Headquarter


China Headquarter with the Largest GMP Cell Manufacturing Facility in South China



Take part in our mission to deliver more effective cancer care and improve patient outcomes.

Ms. Joan Zhang

i. Founding Partner, ABC Capital; President, ABC Group.
ii. Chairman of Board

  • Founding partner, ABC Capital & President, ABC Group

Mr. Wang Liqun

Founder & Chairman, Stone Capital

  • Founder, Stone Capital & Chairman, Stone Capital

Mr. Shen Feiyu

Entrepreneur & Investor

  • Entrepreneur & Investor

Dr. Benjamin Seet

Deputy Group CEO, National Healthcare Group, Singapore

  • Deputy Group CEO, National Healthcare Group Singapore

Dr. Han Deping


  • 20 years of experience in cancer vaccine research and T-cell therapy development.
  • PhD in immunology,
    The Second Military
    Medical University, Shanghai
  • Post doctorate research
    fellow, University of
    Rochester, US.
  • Six years of clinician
    experience in Oncology.

Prof. Jean Paul Thiery

Chief Scientist

  • Principle investigator, Guangzhou Regenerative Medicine and Health, Guangdong Laboratory
  • Emeritus Director of Research, Gustave Roussy Cancer Center, France
  • Former Head, CNRS Unit at Ecole Normale Superieure, Paris, France
  • Former Head, Translational Research Department Institut Curie, Paris, France
  • Former Head, Department of Biochemistry, National University of Singapore
  • Visiting Professor, School of Medicine, University of Bergen, Norway
  • Scientific founder and Chairman of the board, BioCheetah Pte Ltd
    EMBO and Academia Europea member
  • Awardee of Knight of the French National Order of Merit (1997), Laureate of French Academy of Medicine (2000) & Knight in the French Legion of Honor (2009)
    Five patents, Publish 500 peer-reviewed papers , H Index 115.

Dr. Michelle Chen


  • Specialized in operational management, fund raising, business negotiation in biological industry.
  • 14 years of human resource and administration experience in Fortune 500 company.
  • Specialized in data analysis, corporate strategy and process establishment management.

Isaac Chow


  • 25 years of commercial and operations experience in Healthcare and Biomedical sectors.
  • Held senior positions spanning Global and Regional scope, in core Management Teams.
  • Skilled in business transformation and driving strategic initiatives.

Dr. Cecilia Zhang


  • PhD, Department of Biological Sciences, National University of Singapore.
  • In charge of technology transfer with multiple renowned institutes.
  • Post doctorate research in preclinical development of CAR-T/CAR-NK and allogenic cell products.

Vincent Zheng


  • CPA, CFA, Specialized in corporate finance, accounting, auditing, investing, and IPO
  • 8 years experience in big four CPA firm, and 4 years experience as CFO in a HK listed company
  • In charge of several rounds fund raising and the whole process of IPO in a technology company